Abnormal ventricular wall patterning precedes and drives MYBPC3 hypertrophic cardiomyopathy

This study demonstrates that *MYBPC3* mutations drive hypertrophic cardiomyopathy by disrupting early postnatal ventricular wall patterning and maturation through impaired cardiomyocyte proliferation and *Prdm16* downregulation, establishing a developmental origin for the disease and identifying postnatal *Prdm16* restoration as a potential therapeutic strategy.

The Gist

The Big Picture: A Construction Site Gone Wrong

Imagine the human heart is a massive, high-tech skyscraper under construction. For the building to stand strong and function correctly, it needs two things:

1. A solid blueprint (the genetic code).
2. A skilled construction crew that knows exactly when to stop building extra scaffolding and start reinforcing the main walls.

This paper investigates what happens when a specific part of the blueprint—the gene called MYBPC3—is broken. In humans, this broken gene causes a heart disease called Hypertrophic Cardiomyopathy (HCM), where the heart muscle gets dangerously thick and stiff. Sometimes, it also causes Left Ventricular Non-Compaction (LVNC), where the heart looks spongy and full of deep holes (trabeculae) instead of smooth walls.

The researchers asked a big question: Does the heart get sick because the walls get thick as an adult, or was the construction crew confused from the very beginning?

Their answer is surprising: The trouble starts way before the heart is even fully built.

---

The Story of the "Scaffolding" Mistake

1. The Blueprint Error (The Mutation)

Think of the MYBPC3 gene as the foreman of the construction site. Its job is to tell the workers (heart cells) when to stop building the temporary "scaffolding" (trabeculae) inside the heart and start compacting the walls into a solid, smooth structure.

In this study, the researchers created mice with a broken foreman (a mutation in the Mybpc3 gene). They found that when the foreman is missing, the construction crew gets confused.

2. The "Spongy" Phase (Fetal/Early Life)

In a normal heart, the inner walls start out spongy and full of ridges (like a sponge cake). As the baby grows, these ridges get smoothed out and packed tight to form a solid wall. This process is called compaction.

In the mutant mice, the foreman went on strike.

• What happened: The "scaffolding" (trabeculae) kept growing way too big and too long. The heart looked like a deep, spongy cave instead of a smooth tube.
• The Analogy: Imagine a city where the construction crew keeps building extra, unnecessary alleyways and side streets instead of paving over the dirt to make a solid highway. The city is full of deep, confusing holes.
• The Result: The mice had a "spongy" heart (LVNC) right after they were born.

3. The "Over-Compensation" Phase (Childhood/Adulthood)

Here is the twist. In humans, we often see both the spongy holes and the thick walls at the same time. But in these mice, the spongy phase was temporary.

• What happened next: As the mice grew older (around 1 week old), the spongy holes started to disappear, but the heart didn't just become normal. Instead, the remaining walls started to grow massively thick.
• The Analogy: Because the crew spent so much time building the wrong kind of alleyways, they panicked later. They decided to reinforce the main highway so heavily that it became a massive, concrete wall, blocking traffic and making the building rigid.
• The Result: The mice developed the classic thick-heart disease (HCM) seen in adults.

The Key Discovery: The "spongy" phase wasn't a separate disease; it was the early warning sign that the construction crew was confused. That confusion set the stage for the thick, dangerous walls that appeared later.

---

The "Manager" Who Got Fired (Prdm16)

The researchers wanted to know why the crew got confused. They found a specific "manager" protein called Prdm16.

• Normal Job: Prdm16 is like a strict quality control manager. Its job is to tell the heart cells: "Stop growing so fast, stop building extra scaffolding, and start maturing into strong, efficient muscle cells."
• The Breakdown: When the foreman (MYBPC3) was missing, the manager (Prdm16) got fired (its levels dropped) right when the baby mice were growing up.
• The Consequence: Without the manager, the cells kept acting like babies. They kept dividing (proliferating) and building extra scaffolding instead of growing up to be strong, mature muscle. Eventually, they grew too big (hypertrophy) to compensate for the chaos.

The "Magic Fix" (The Experiment)

To prove that the missing manager was the real problem, the scientists performed a rescue mission.

• They took the mutant mice and re-installed the manager (Prdm16) just as the mice were growing up.
• The Result: Even though the original blueprint (MYBPC3) was still broken, the heart did not get thick. The cells stopped acting like confused babies and grew normally.

The Analogy: It's like having a broken blueprint, but if you hire a really good substitute manager, the construction crew can still build a solid skyscraper.

---

Why Does This Matter?

1. It's a Developmental Disease: This study shows that adult heart disease often starts as a developmental error. The heart doesn't just "wear out"; it was built wrong from the start because the cells didn't know when to stop growing and start maturing.
2. The "Spongy" Heart is a Clue: If a patient has a heart that looks spongy (LVNC) or has deep crypts, it might be a sign that they are on a path to developing thick-heart disease (HCM) later in life.
3. A New Way to Treat It: Instead of just trying to shrink the thick heart in adults (which is hard), doctors might be able to fix the maturation process in children or young adults. By boosting the "manager" protein (Prdm16), we might be able to stop the heart from getting dangerously thick in the first place.

Summary in One Sentence

The heart gets sick because a broken gene confuses the construction crew early in life, causing them to build a spongy, messy structure that later over-corrects into a dangerously thick wall; but if we can restore the "manager" protein that tells the cells how to grow up, we can prevent the disease entirely.

Technical Summary

1. Problem Statement

Genetic cardiomyopathies, particularly those caused by MYBPC3 mutations, exhibit significant phenotypic heterogeneity, often presenting as a mix of Hypertrophic Cardiomyopathy (HCM) and Left Ventricular Non-Compaction (LVNC). While MYBPC3 is a well-established cause of HCM, the developmental origins of the overlapping LVNC features (excessive trabeculation and myocardial crypts) and the mechanistic link between early developmental defects and adult-onset hypertrophy remain poorly defined. It is unclear whether these distinct phenotypes represent separate disease entities or a continuous developmental trajectory where early patterning errors drive later pathological remodeling.

2. Methodology

The study employed a multi-disciplinary approach integrating human clinical data, humanized mouse models, and advanced molecular profiling:

• Human Cohort Analysis: Clinical and genetic characterization of two families carrying MYBPC3 frameshift mutations (p.Pro108Serfs9 and p.Arg891Alafs160), revealing a spectrum of phenotypes ranging from isolated LVNC to mixed HCM/LVNC.
• Humanized Mouse Models: Generation of two knock-in mouse lines using CRISPR-Cas9 to recapitulate the patient-derived frameshift mutations (Mybpc3 p.Pro109Serfs12 and Mybpc3 p.Arg887Alafs160). A third model (Mybpc3 p.Arg502Trp missense) was used for comparison.
• Phenotypic Profiling: Comprehensive assessment from fetal stages (E15.5) through adulthood using:
  • Imaging: Cardiac MRI (CMRI), echocardiography, and histology (H&E, Masson's Trichrome, WGA staining).
  • Ultrastructure: Transmission Electron Microscopy (TEM) for sarcomere and mitochondrial integrity.
  • Lineage Tracing: Hey2CreERT2 crossed with Rosa26mTmG reporters to track compact myocardium (CM) vs. trabecular myocardium (TM) cell fate.
• Transcriptomics: Bulk RNA-seq performed at critical developmental time points (E15.5, P1, P7, and adulthood) followed by Gene Set Enrichment Analysis (GSEA).
• Functional Rescue: Generation of a conditional Rosa26-Prdm16 transgenic line to test if restoring Prdm16 expression postnatally could attenuate the hypertrophic phenotype in Mybpc3 null mice.

3. Key Contributions

• Developmental Continuity: Establishes that MYBPC3-related cardiomyopathy is not solely an adult-onset disease but a continuum starting with transient developmental defects (hypertrabeculation/LVNC-like) that precede and drive adult HCM.
• Mechanistic Link: Identifies ventricular wall patterning defects as the primary driver, specifically the failure to restrict Hey2+ compact cardiomyocytes to the outer wall, leading to ectopic invasion of the trabecular layer.
• Molecular Effector: Discovers Prdm16 as a critical downstream effector of Mybpc3. The study demonstrates that Mybpc3 loss leads to postnatal Prdm16 downregulation, which removes a brake on hypertrophic gene programs.
• Therapeutic Strategy: Provides proof-of-concept that postnatal restoration of Prdm16 can attenuate cardiomyocyte hypertrophy, suggesting a novel therapeutic window for early intervention.

4. Key Results

A. Phenotypic Progression: From Hypertrabeculation to Hypertrophy

• Fetal/Neonatal Stage (P1): Homozygous mutant mice exhibited severe hypertrabeculation, enlarged crypts, and a thin compact myocardium, mimicking human LVNC. However, cardiomyocyte size was normal at this stage.
• Postnatal Transition (P7): The hypertrabeculation phenotype resolved, but was replaced by overt pathological hypertrophy (increased wall thickness, chamber dilation) and sarcomere disarray.
• Adulthood: Mutant mice displayed classic HCM features: asymmetric hypertrophy, interstitial fibrosis, sarcomere disarray, and mitochondrial remodeling. Notably, the overt LVNC features seen in humans were transient in mice, resolving as the heart transitioned to the hypertrophic state.

B. Molecular Dysregulation and Cell Cycle

• Transcriptomic Shifts: RNA-seq revealed that P1 and P7 were critical windows.
  • P1: Mutants showed a "fetal-like" profile with upregulated cell cycle pathways (E2F targets, G2/M checkpoint) and downregulated oxidative metabolism. This indicated a failure of cardiomyocytes to exit the cell cycle and mature.
  • P7: A shift occurred where metabolic pathways were aberrantly upregulated alongside persistent cell cycle activity, leading to a hypertrophic transcriptional signature.
• Proliferation Defect: There was a 2-fold increase in trabecular cardiomyocyte proliferation in mutants at P1, reversing the normal gradient where the compact myocardium is more proliferative than the trabeculae. This led to impaired ventricular compaction.

C. Lineage Tracing and Patterning Defects

• Hey2+ Lineage Expansion: Using Hey2CreERT2 lineage tracing, the study showed that in mutants, Hey2+ cells (normally restricted to the compact myocardium) invaded the trabecular layer during fetal and early postnatal development.
• Prdm16 Ectopic Expression: This invasion was accompanied by ectopic expression of the transcription factor Prdm16 in the trabeculae.
• Postnatal Restriction: By P7, Hey2+ cells were restricted back to the outer wall in mutants, but the inner trabecular myocardium had already undergone accelerated hypertrophy concurrent with Prdm16 downregulation.

D. The Prdm16 Rescue

• Downregulation: Prdm16 mRNA and protein levels were significantly reduced in the inner myocardium of mutants by P7, coinciding with the onset of hypertrophy.
• Rescue Experiment: Postnatal induction of Prdm16 expression in Mybpc3 null mice (via Myh6MerCreMer and Rosa26-Prdm16) significantly attenuated cardiomyocyte hypertrophy and reduced ventricular wall thickness.
• Uncoupling: Interestingly, while Prdm16 restoration reduced structural hypertrophy, it did not fully suppress the activation of fetal stress markers (e.g., Nppa), suggesting Prdm16 specifically regulates the growth response rather than the upstream stress signaling.

5. Significance

• Redefining Disease Onset: The study challenges the view of HCM as purely an adult maladaptive response, proposing instead that developmental patterning errors (specifically defective ventricular wall maturation) are the root cause.
• Sarcomere-Development Link: It reveals a non-canonical role for sarcomeric proteins (MYBPC3) in regulating cardiomyocyte proliferation, cell cycle exit, and lineage specification during development.
• Therapeutic Implications: The identification of Prdm16 as a key node linking sarcomere dysfunction to hypertrophy offers a new therapeutic target. The finding that postnatal Prdm16 restoration can mitigate hypertrophy suggests that early intervention during the critical P1–P7 window (or equivalent in humans) could prevent the progression to overt heart failure.
• Modeling Heterogeneity: The mouse models successfully recapitulate the transient LVNC-like phase and subsequent HCM, providing a robust platform to study the transition between these overlapping cardiomyopathy phenotypes.